cnbc.com / .cnbc-com-health-care / Page 2

Novo Nordisk said Hims & Hers has "failed to adhere to the law which prohibits mass sales of compounded drugs" under the "false guise" of personalization.

Insurers such as CVS and UnitedHealthcare will implement the changes across commercial, Medicare and Medicaid plans, benefiting 257 million Americans.

The FDA announced a new national priority voucher plan that aims to cut drug review times, while Headspace launches direct-to-consumer offering.

The launch of the injection faces potential threats, including the Trump administration's proposed cuts to federal funding for HIV prevention efforts.

Karen Knudsen is leading Sean Parker's cancer immunotherapy incubator where philanthropy and venture capital meet.

It is the panel's first meeting with Kennedy's newly appointed members, many of whom are well-known vaccine critics.

The health insights tracked by Oura Ring will be utilized by Maven Clinic's doctors and care teams as part of a new partnership.

The lawmakers accuse Pfizer, Merck, J&J, AbbVie and Amgen of paying little to nothing in federal taxes despite generating billions of dollars annually.

Sword Health is pulling in additional capital as it expands into mental health care with a new artificial intelligence tool.

Companies like AstraZeneca, Daiichi Sankyo, Pfizer and Merck are learning from previous setbacks in the ADC space to improve their efficacy and safety.